Provided by Tiger Trade Technology Pte. Ltd.

BioAtla, Inc.

0.2106
+0.020510.78%
Post-market: 0.1650-0.0456-21.65%19:56 EST
Volume:3.00M
Turnover:621.44K
Market Cap:13.37M
PE:-0.18
High:0.2238
Open:0.1933
Low:0.1925
Close:0.1901
52wk High:1.43
52wk Low:0.1400
Shares:63.46M
Float Shares:50.38M
Volume Ratio:0.57
T/O Rate:5.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1495
EPS(LYR):-1.4365
ROE:-813.88%
ROA:-105.08%
PB:-0.43
PE(LYR):-0.15

Loading ...

BioAtla Faces Nasdaq Trading Suspension and Potential Delisting

TIPRANKS
·
5 hours ago

BioAtla Faces Nasdaq Delisting Over Listing Rule Violations

Reuters
·
6 hours ago

BioAtla Inc. Announces Date for Upcoming Special Meeting of Stockholders

Reuters
·
Jan 31

BioAtla Pursues Share Consolidation Amid Nasdaq Compliance Dispute

TIPRANKS
·
Jan 31

BioAtla files $200M mixed securities shelf

TIPRANKS
·
Jan 17

Bioatla Inc : Files for Mixed Shelf Offering of up to $200 Mln - SEC Filing

THOMSON REUTERS
·
Jan 17

BioAtla initiated with a Buy at Rodman & Renshaw

TIPRANKS
·
Jan 14

BioAtla Creates Super-Voting Share to Advance Reverse Split

TIPRANKS
·
Jan 13

BioAtla Inc. Held Special Shareholder Meeting

Reuters
·
Jan 13

BioAtla Partners with Inversagen AI to Advance Oz-V Senolytic Therapy for OPSCC

Reuters
·
Dec 31, 2025

Bioatla and Gatc Health Announce a $40 Million Special Purpose Vehicle (Spv) Transaction to Advance Ozuriftamab Vedotin (Oz-V) Into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (Opscc)

THOMSON REUTERS
·
Dec 31, 2025

Bioatla Inc: to Retain 65% Ownership of Oz-V Across All Solid Tumor Indications After Completion of Spv Transaction

THOMSON REUTERS
·
Dec 31, 2025

Bioatla Inc: Phase 3 Trial Execution for Oz-V Enrollment Anticipated to Begin Early 2026

THOMSON REUTERS
·
Dec 31, 2025

Bioatla Inc: Co & Gatc Health to Collaborate With Inversagen AI for Research and Development of Cab Senolytic Therapies

THOMSON REUTERS
·
Dec 31, 2025

Bioatla Inc: Will Lead Phase 3 Trial Execution for Oz-V in Opscc Through Data Readout for Potential Accelerated Approval

THOMSON REUTERS
·
Dec 31, 2025

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

GlobeNewswire
·
Dec 31, 2025

BioAtla Inc. Held Special Shareholder Meeting

Reuters
·
Dec 31, 2025

BioAtla Inc. Announces Date for Upcoming Special Meeting of Stockholders

Reuters
·
Nov 25, 2025

BioAtla Secures $7.5 Million Pre-Paid Advance Financing from Yorkville and Anson Funds

Reuters
·
Nov 21, 2025

BioAtla Agrees to $22.5 Million in Financing Agreements

MT Newswires Live
·
Nov 21, 2025